Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
As healthcare costs continue to rise, biosimilars offer new therapeutic options with the potential for cost savings to the healthcare system. With anticipated savings, biosimilars bring hope that there will be expanded access for patients to not only these known therapies, but also to new innovative medicines. At Amgen, serving patients is at the core of what we do and it is why we’re using our more than 35 years of biologics experience to develop high-quality biosimilars.
First, in pharmerging markets, both governments and patients struggle to pay for biosimilars, which encouraged the demand of biosimilars, therefore in the future the biosimilars will grow around 20%.
Second, generally, biosimilars industry is still in their infancy in China. It is commonly believed that the next 10 to 15 years is the golden period of the development of biosimilars.
Third, for the biosimilars industry, technical barriers will be much smaller, in the next few years, there will be more and more enterprises going into biosimilars industry.
Forth, most of biosimilars manufacturer are concentrated in US, Germany, UK and other developed countries.
At last, through the research we tend to believe that the biosimilars, now is a chance for newcomers and they will greatly change the industry.
Market Analysis and Insights: Global Biosimilar Drug Market
The global Biosimilar Drug market is valued at US$ XX million in 2019. The market size will reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
Global Biosimilar Drug Scope and Market Size
Biosimilar Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilar Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.
Segment by Type
Injection
Tablets
Other Types
Segment by Application
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
By Company
Amgen
Eli Lilly
Novartis
CP Guojian Pharma
Biotech Pharma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
As healthcare costs continue to rise, biosimilars offer new therapeutic options with the potential for cost savings to the healthcare system. With anticipated savings, biosimilars bring hope that there will be expanded access for patients to not only these known therapies, but also to new innovative medicines. At Amgen, serving patients is at the core of what we do and it is why we’re using our more than 35 years of biologics experience to develop high-quality biosimilars.
First, in pharmerging markets, both governments and patients struggle to pay for biosimilars, which encouraged the demand of biosimilars, therefore in the future the biosimilars will grow around 20%.
Second, generally, biosimilars industry is still in their infancy in China. It is commonly believed that the next 10 to 15 years is the golden period of the development of biosimilars.
Third, for the biosimilars industry, technical barriers will be much smaller, in the next few years, there will be more and more enterprises going into biosimilars industry.
Forth, most of biosimilars manufacturer are concentrated in US, Germany, UK and other developed countries.
At last, through the research we tend to believe that the biosimilars, now is a chance for newcomers and they will greatly change the industry.
Market Analysis and Insights: Global Biosimilar Drug Market
The global Biosimilar Drug market is valued at US$ XX million in 2019. The market size will reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
Global Biosimilar Drug Scope and Market Size
Biosimilar Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilar Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.
Segment by Type
Injection
Tablets
Other Types
Segment by Application
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
By Company
Amgen
Eli Lilly
Novartis
CP Guojian Pharma
Biotech Pharma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
